KYMRHealthcare · BiotechnologyThe 24 Wall Street analysts covering Kymera Therapeutics, Inc. hold a median 12-month price target of $139 — +18.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 26 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Kymera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Accruals (33): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on KYMR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +18.3% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Oct 2026 | Raymond James | Initiates | Outperform | $140 |
| 5 Oct 2026 | Citigroup | Maintains | Buy | $135 → $150 |
| 22 Sept 2026 | Stifel | Maintains | Buy | — |
| 22 Sept 2026 | Stifel | Maintains | Buy | $132 → $152 |
| 14 Sept 2026 | B of A Securities | Maintains | Buy | $123 → $144 |
| 14 Sept 2026 | B of A Securities | Maintains | Buy | — |
| 10 Sept 2026 | Wolfe Research | Upgrade | Outperform | — |
| 10 Sept 2026 | Wolfe Research | Upgrade | Outperform | — |
| 31 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 31 Aug 2026 | Guggenheim | Maintains | Buy | $135 → $170 |
| 27 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 27 Aug 2026 | Wells Fargo | Maintains | Overweight | $116 → $151 |
| 6 Aug 2026 | Barclays | Maintains | Overweight | $133 → $139 |
| 6 Aug 2026 | Barclays | Maintains | Overweight | — |
| 30 July 2026 | Deutsche Bank | Initiates | Hold | — |
| 30 July 2026 | Deutsche Bank | Initiates | Hold | $120 |
| 28 July 2026 | Guggenheim | Maintains | Buy | — |
| 28 July 2026 | Guggenheim | Maintains | Buy | $125 → $135 |
| 16 July 2026 | Mizuho | Maintains | Outperform | $120 → $140 |
| 16 July 2026 | Mizuho | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KYMR appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Kymera Therapeutics, Inc. returned +93.1% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 4% of US stocks
Cheaper than 15% of US stocks
Cheaper than 91% of US stocks
Higher than 98% of US stocks
Higher than 95% of US stocks
Higher than 13% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kymera Therapeutics, Inc. has a market value of $9.1B and an enterprise value of $8.6B.
Revenue in the twelve months to 30 June 2026: $105.0M. The latest quarter grew 466.4% year on year.
Net income over the same four quarters: −$299.6M, a −285.3% net margin.
Diluted earnings per share, trailing twelve months: $−3.24.
Free cash flow in the twelve months to 30 June 2026: −$238.0M.
Trailing P/E: −30.0×; forward P/E: −21.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Kymera Therapeutics, Inc. employs 273 people — $385K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kymera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Kymera Therapeutics said it will report its third-quarter 2026 financial results on October 29, 2026. The company will hold a video conference call and webcast at 8:30 a.m. ET that day.
Why it matters — KYMR watchers can follow the scheduled results announcement and hear the company’s accompanying webcast.
Kymera Therapeutics is advancing its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma reaching key milestones amid competition in the field.
Why it matters — The trial milestones and competitive context are relevant to watchers tracking the progress of Kymera’s pipeline.
Purcell & Lefkowitz LLP announced an investigation of Kymera Therapeutics on behalf of shareholders. The firm is examining whether directors breached fiduciary duties in connection with recent corporate actions.
Why it matters — The investigation concerns Kymera’s directors and recent corporate actions, an issue shareholders may follow.
Kymera Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The presentation covers the company's activities and remarks made during the conference.
Why it matters — The transcript gives KYMR watchers direct visibility into the company's latest public statements and updates shared at a major industry conference.
Kymera Therapeutics presented at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation published by Seeking Alpha. The company's remarks at the event are now publicly available.
Why it matters — A KYMR watcher would care because the transcript offers insight into the company's latest updates and messaging shared directly with investors at a major industry conference.
The 24 Wall Street analysts covering Kymera Therapeutics, Inc. have a median 12-month price target of $139, with estimates ranging from $111 to $180. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 24 analysts covering Kymera Therapeutics, Inc., 22 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kymera Therapeutics, Inc. 82 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 26 Oct 2026, Kymera Therapeutics, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 24 analysts implies +18.3% from the last close, and Ticker Nerd's factor model ranks Kymera Therapeutics, Inc. 82 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kymera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $111 to $180 over the next 12 months.
Kymera Therapeutics, Inc. returned +93.1% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Kymera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines that use targeted protein degradation to address disease-causing proteins.
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026". Kymera Therapeutics said it will report its third-quarter 2026 financial results on October 29, 2026. The company will hold a video conference call and webcast at 8:30 a.m. ET that day.
Kymera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines that use targeted protein degradation to address disease-causing proteins. The company’s work centers on harnessing the body’s natural protein recycling systems to create oral therapies designed for conditions that are difficult to treat with conventional approaches. Its current programs span immunology, inflammation, and oncology, with research aimed at diseases such as atopic dermatitis, hidradenitis suppurativa, autoimmune disorders, and certain cancers. Kymera Therapeutics Inc. operates through a differentiated drug-discovery platform that supports both internal pipeline development and strategic research collaborations. Headquartered in Watertown, Massachusetts, the company plays a specialized role in the biotechnology market by advancing novel treatment approaches for serious diseases.
CEO Dr. Nello Mainolfi M.D., Ph.D. · 273 employees · United States · https://www.kymeratx.com
